In mouse endometrial and bladder cancers, loss of PTEN and LKB1 leads to activation of the AKT/mTOR pathway and results in tumors sensitivity to PI3K and mTOR inhibition. This evidence concerns the gene AKT1 and urinary bladder cancer.